Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Varl30Met: A phase III, open-label study

Journal of the Neurological Sciences

Volumn 362, Issue , 2016, Pages 266-271

  Yukio, Ando ^a   Yoshiki, Sekijima ^b   Konen, Obayashi ^c   Taro, Yamashita ^a   Mitsuharu, Ueda ^a   Yohei, Misumi ^a   Hiroshi, Morita ^b   Katsuyuki, MacHii ^d   Makoto, Ohta ^d   Ami, Takata ^d   Shû Ichi, Ikeda ^b  

^a KUMAMOTO UNIVERSITY   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

^d PFIZER INC   (United States)

Author keywords

Amyloid; familial amyloid polyneuropathy; tafamidis; transthyretin amyloidosis; TTR non Val30Met; TTR Val30Met

Indexed keywords

PREALBUMIN; TAFAMIDIS; BENZOXAZOLE DERIVATIVE; METHIONINE; VALINE;

ADULT; ARTICLE; BACTERIAL PNEUMONIA; BODY MASS; CATARACT; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FAMILIAL AMYLOID POLYNEUROPATHY; FEMALE; GENOTYPE; HEART STROKE VOLUME; HEART VENTRICLE SEPTUM; HUMAN; INSOMNIA; MALE; MIDDLE AGED; MOBILIZATION; MULTICENTER STUDY; MUSCLE WEAKNESS; NUTRITIONAL STATUS; ONSET AGE; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; SUDDEN DEATH; TREATMENT DURATION; VITREOUS OPACITY; VOMITING; AGED; AMYLOID NEUROPATHIES, FAMILIAL; CLINICAL TRIAL; ECHOCARDIOGRAPHY; FOLLOW UP; GENETICS; JAPAN; METABOLISM; PHARMACOGENETICS; YOUNG ADULT;

ADULT; AGED; AMYLOID NEUROPATHIES, FAMILIAL; BENZOXAZOLES; BODY MASS INDEX; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; JAPAN; MALE; METHIONINE; MIDDLE AGED; PHARMACOGENETICS; PREALBUMIN; VALINE; YOUNG ADULT;

EID: 84962220171     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2016.01.046     Document Type: Article

References (25)

1. Coutinho P, Martins da Silva A, Lopes Lima J, Resende Barbosa A. Forty years of experience with type I amyloid neuropathy. Review of 483 cases. In: Glenner GG, Pinho e Costa P, Falcao de Freitas A, editors. Amyloid and amyloidosis. Amsterdam: Excerpta Medica; c1980; p. 88-98.
2. Y. Kato-Motozaki, K. Ono, K. Shima, A. Morinaga, T. Machiya, I. Nozaki, A. Shibata-Hamaguchi, and et al. Epidemiology of familial amyloid polyneuropathy in Japan: Identification of a novel endemic focus J. Neurol. Sci. 270 2008 Jul 15 133 140
3. V. Planté-Bordeneuve, and G. Said Familial amyloid polyneuropathy Lancet Neurol. 10 2011 Dec 1086 1097
4. Y. Ando, T. Coelho, J.L. Berk, M.W. Cruz, B.G. Ericzon, S. Ikeda, W.D. Lewis, and et al. Guideline of transthyretin-related hereditary amyloidosis for clinicians Orphanet. J. Rare Dis. 8 2013 31
5. X. Hou, M.I. Aguilar, and D.H. Small Transthyretin and familial amyloidotic polyneuropathy. recent progress in understanding the molecular mechanism of neurodegeneration FEBS J. 274 2007 Apr 1637 1650
6. M.J. Saraiva, S. Birken, P.P. Costa, and D.S. Goodman Family studies of the genetic abnormality in transthyretin (prealbumin) in Portuguese patients with familial amyloidotic polyneuropathy Ann. N. Y. Acad. Sci. 435 1984 86 100
7. C. Rapezzi, C.C. Quarta, L. Riva, S. Longhi, I. Gallelli, M. Lorenzini, P. Ciliberti, and et al. Transthyretin-related amyloidoses and the heart: A clinical overview Nat. Rev. Cardiol. 7 2010 Jul 398 408
8. Y. Ando, M. Nakamura, and S. Araki Transthyretin-related familial amyloidotic polyneuropathy Arch. Neurol. 62 2005 Jul 1057 1062
9. H. Koike, K. Misu, S. Ikeda, Y. Ando, M. Nakazato, E. Ando, M. Yamamoto, and et al. Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: Early- vs late-onset form Arch. Neurol. 59 2002 Nov 1771 1776
10. Y. Sekijima Transthyretin (ATTR) amyloidosis: Clinical spectrum, molecular pathogenesis and disease-modifying treatments J. Neurol. Neurosurg. Psychiatry 20 2015 Jan
11. C.E. Bulawa, S. Connelly, M. Devit, L. Wang, C. Weigel, J.A. Fleming, J. Packman, and et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade Proc. Natl. Acad. Sci. U. S. A. 109 2012 Jun 12 9629 9634
12. European Medicines Agency Vyndaqel, tafamidis - EPAR summary for the public 2013 Available from: Http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Summary-for-the-public/human/002294/WC500117861.pdf
13. L.J. Scott Tafamidis: A review of its use in familial amyloid polyneuropathy Drugs 74 2014 Aug 1371 1378
14. Pharmaceuticals and Medical Devices Agency J. [cited 2015, Feb 4]. Available from: Http://www.pmda.go.jp/english/service/pdf/drugs/vyndaqel-sep2013-e.pdf
15. T. Coelho, L.F. Maia, A. Martins da Silva, M. Waddington Cruz, V. Planté-Bordeneuve, P. Lozeron, S. OB, and et al. Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial Neurology 79 2012 Aug 21 785 792
16. T. Coelho, L.F. Maia, A.M. da Silva, M.W. Cruz, V. Planté-Bordeneuve, O.B. Suhr, I. Conceiçao, and et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy J. Neurol. 260 2013 Nov 2802 2814
17. G. Merlini, V. Planté-Bordeneuve, D.P. Judge, H. Schmidt, L. Obici, S. Perlini, J. Packman, and et al. Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis J. Cardiovasc. Transl. Res. 6 2013 Dec 1011 1020
18. P.J. Dyck, J.L. Davies, W.J. Litchy, and P.C. O'Brien Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester diabetic neuropathy study cohort Neurology 49 1997 Jul 229 239
19. P.J. Dyck, L.J. Melton 3rd, P.C. O'Brien, and S. FJ Approaches to improve epidemiological studies of diabetic neuropathy: Insights from the Rochester Diabetic Neuropathy Study Diabetes 46 Suppl. 2 1997 Sep S5 S8
20. P.J. Dyck, W.J. Litchy, J.R. Daube, C.M. Harper, J. Davies, and P.C. O'Brien Individual attributes versus composite scores of nerve conduction abnormality: Sensitivity, reproducibility, and concordance with impairment Muscle Nerve 27 2003 Feb 202 210
21. P.J. Dyck, P.C. O'Brien, W.J. Litchy, C.M. Harper, and C.J. Klein Monotonicity of nerve tests in diabetes: Subclinical nerve dysfunction precedes diagnosis of polyneuropathy Diabetes Care 28 2005 Sep 2192 2200
22. E.J. Vinik, R.P. Hayes, A. Oglesby, E. Bastyr, P. Barlow, S.L. Ford-Molvik, and A.I. Vinik The development and validation of the Norfolk QOL-DN, a new measure of patients' perception of the effects of diabetes and diabetic neuropathy Diabetes Technol. Ther. 7 2005 Jun 497 508
23. O. Suhr, A. Danielsson, G. Holmgren, and L. Steen Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy J. Intern. Med. 235 1994 May 479 485
24. H. Koike, F. Tanaka, R. Hashimoto, M. Tomita, Y. Kawagashira, M. Iijima, J. Fujitake, and et al. Natural history of transthyretin Val30Met familial amyloid polyneuropathy: Analysis of late-onset cases from non-endemic areas J. Neurol. Neurosurg. Psychiatry 83 2012 Feb 152 158
25. Y. Sekijima Recent progress in the understanding and treatment of transthyretin amyloidosis J. Clin. Pharm. Ther. 39 2014 Jun 225 233